New data from an open-label extension study of Alnylam Pharmaceuticals, Inc.
(NASDAQ:ALNY)’s Onpattro shows long-term efficacy and sustained treatment
benefit for polyneuropathy of hereditary ATTR (hATTR) amyloidosis. The
long-term data shows the drugs ability to reverse or halt neuropathy
progression, the company said. Over the weekend, Cambridge, Mass.-based Alnylam
presented the data from the Global Open Label Extension study at the 2019
Peripheral Nerve Society (PNS) Annual Meeting in Italy, as well as a new
analysis from the APOLLO Phase III study of patisiran.
Alnylam
Pharmaceuticals, Inc. (NASDAQ:ALNY), a Healthcare sector firm, traded 479560
shares in last trading session with closing price of $71.80 per share. Company
gross margin stands at 94.00% whereas its return on investment (ROI) is
-59.70%. Stock value has moved between $60.34 – 123.79 in last one year.
Analyst’s mean target price for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is
$121.56 while analysts mean recommendation is 2.10. ALNY EPS growth this year
is -39.80%.
On last trading day, Brighthouse Financial, Inc. (NASDAQ:BHF) shares closed at
$38.12 per share. BHF market capitalization is 4453.94. Analyst’s mean target
price for Brighthouse Financial, Inc. (NASDAQ:BHF) is $41.69 whereas analysts
mean recommendation is 3.20. Its weekly performance is 1.25% while year to date
(YTD) performance is 25.07%.
In last session Markel Corporation (NYSE:MKL) traded 23363 shares and was
closed at $1077.75. Analyst’s mean target price for MKL is $1066.67 while
analysts mean recommendation is 2.70. Company is -12.26% away from its 52 week
high and is moving 13.43% ahead of its 52 week low. MKL return on assets is
1.50%. Markel Corporation (NYSE:MKL) quarterly performance is 9.34% while its
price to sale ratio is 1.96.
Lear Corporation (NYSE:LEA), a Consumer Goods sector firm, traded 503569 shares
on last trading day with closing price of $138.09 per share. Company gross
margin stands at 11.00% whereas its return on investment (ROI) is 21.20%. Stock
value has moved between $114.12 – 203.07 in last one year. Analyst’s mean
target price for Lear Corporation (NYSE:LEA) is $171.50 while analysts mean
recommendation is 2.10. LEA EPS growth this year is 2.70%.
